Mian M. Shahzad, MD, PhD
Preliminary research has shown that harnessing the immune system can lead to potentially viable and efficacious therapies for patients with advanced ovarian cancer; therefore, combination approaches with checkpoint inhibitors could have an impact on outcomes.
"If we can wake up the immune system to recognize a foreign [entity] and attack it, we may be able to make a big dent in [treatment],” said Mian M. Shahzad, MD, PhD. “There are also ongoing studies with oncolytic virotherapy."
In a presentation during the 2019 OncLive®
State of the Science Summit™ on Ovarian Cancer, Shahzad, a gynecologic oncologist in The Center for Women’s Oncology, Moffitt Cancer Center, discussed the use of checkpoint inhibition in advanced ovarian cancer.
... to read the full story